scholarly journals Eruptive Xanthomas Caused by Primary Type V Hyperlipoproteinemia

Author(s):  
Yoshihiro Nakamura ◽  
Tsuyoshi Watanabe ◽  
Naoho Takizawa ◽  
Yoshiro Fujita
PEDIATRICS ◽  
1977 ◽  
Vol 59 (4) ◽  
pp. 513-525
Author(s):  
Peter O. Kwiterovich ◽  
J. Ramsay Farah ◽  
W. Virgil Brown ◽  
Paul S. Bachorik ◽  
Stephen B. Baylin ◽  
...  

Primary type V hyperlipoproteinemia was identified in two preadolescent children. The propositus (kindred N) was a 10-year-old girl with severely creamy plasma, lipemia retinalis, hypertriglyceridemia (triglyceride level, 6,800 mg/100 ml), and hypercholesterolemia (cholesterol level, 490 mg/100 ml). Her parents and an 8-year-old sister all had endogenous hypertriglyceridemia (type IV hyperlipoproteinemia). In kindred A, an 11-year-old boy had triglyceride levels as high as 1,100 mg/100 ml and recurrent abdominal pain. His father had type V hyperlipoproteinemia; his mother was normal. All three of his older teenage siblings had type IV hyperlipoproteinemia. The enzymatic activities of lipoprotein lipase (LPL), hepatic triglyceride lipase (HTL), and histaminase (H) were studied in postheparin plasma. The LPL level was low in the children and both parents in kindred N. LPL level in kindred A was normal, except for one child with type IV hyperlipoproteinemia. HTL level was normal to above normal in both kindreds. Most patients had a normal H level, but one parent (kindred N) had no preheparin H and very low levels of postheparin H. There was a strong correlation (r = 0.58, significant at < 1% level) between the release of LPL and H but not between HTL and H (r = 0.22). The mean (± 1 S.D.) levels of the enzymes were as follows: LPL, 2.8 ± 0.7 µmol/ml/hr in kindred N and 5.4 ± 2.2 µmol/ml/hr in kindred A; H, 13.4 ± 6.8 units/ml in kindred N and 22.0 ± 11.9 units/ml in kindred A; and HTL, 18.0 ± 7.1 µmol/ml/hr in kindred N and 14.9 ± 6.3 µmol/ml/hr in kindred A. The enzymatic activities of kindreds N and A were significantly different for LPL (P < .001) and H (.025 < P < .05) but not for HTL. All but one child had at least one high insulin level, which was accompanied by hyperglycemia in two children. The hypertriglyceridemia in all but one child was ameliorated on therapeutic diets. These data suggest that the genetic basis of the hypertriglyceridemia in these two families is different and that hyperchylomicronemia in childhood is not confined to the rare type I hyperlipoproteinemia.


JAMA ◽  
1977 ◽  
Vol 238 (23) ◽  
pp. 2518 ◽  
Author(s):  
Daniel Yeshurun

2005 ◽  
Vol 20 (3) ◽  
pp. 502 ◽  
Author(s):  
Jeong Rang Park ◽  
Tae Sik Jung ◽  
Jung Hwa Jung ◽  
Gyeong-Won Lee ◽  
Me Ae Kim ◽  
...  

JAMA ◽  
1977 ◽  
Vol 238 (23) ◽  
pp. 2518-2520 ◽  
Author(s):  
D. Yeshurun

2001 ◽  
Vol 13 (3) ◽  
pp. 175
Author(s):  
Hyun Jin Mo ◽  
Jong Yuk Yi ◽  
Chul Jong Park ◽  
Hyun-shik Son

1977 ◽  
Vol 87 (5) ◽  
pp. 526 ◽  
Author(s):  
BARRY H. GREENBERG

Author(s):  
Enzo Manzato ◽  
Adriana Gasparotto ◽  
Raffaella Marin ◽  
Giovannella Baggio ◽  
Goretta Baldo ◽  
...  

1987 ◽  
Vol 33 (3) ◽  
pp. 423-428 ◽  
Author(s):  
H L Verrill ◽  
R E Girgis ◽  
R E Easterling ◽  
B S Malhi ◽  
W F Mueller

Abstract A patient with severe type V hyperlipoproteinemia and chronic end-stage renal disease received a renal transplant and therapy with cyclosporine. Concentrations of the drug in plasma as determined by liquid chromatography appeared extraordinarily high for the dose ingested. When we measured the drug in the plasma, plasma cleared by ultracentrifugation, leukocytes, erythrocytes, and whole blood, we found that the high concentrations of cyclosporine were associated with the chylomicrons that always were present in this patient's blood. Cyclosporine added directly to this patient's plasma was less associated with the plasma lipids. Isolated lymphocytes and kidney slices incubated with plasma from this patient bound no more drug than when incubated with nonhyperlipemic plasma containing cyclosporine at a normal therapeutic concentration. We conclude that the cyclosporine associated with the chylomicrons in this patient was not biologically available to either lymphocytes or kidney tissue. We strongly recommend the use of chylomicron-cleared plasma for therapeutic drug monitoring of cyclosporine in type V hyperlipoproteinemic patients.


1985 ◽  
Vol 56 (2) ◽  
pp. 157-167 ◽  
Author(s):  
Michael Aviram ◽  
Bianca Furman ◽  
J.Gerald Brook

1980 ◽  
Vol 23 (1) ◽  
pp. 114-118 ◽  
Author(s):  
JAMES L. Reinertsen ◽  
Ernst J. Schaefer ◽  
H. Bryan Brewer ◽  
Haralampos M. Moutsopoulos

Sign in / Sign up

Export Citation Format

Share Document